Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Psoriasis Article
This is a selection made from among articles on Drug Treatment Psoriasis. For a permanent link to this article, or to bookmark it for future reading, click here.
Signs and Symptoms of Drug Abuse
from: Drug abuse, involves the excessive and repeated use of a substance to escape reality to produce pleasure despite its destructive effects. The substances abused can be illegal drugs such as opium, cocaine, marijuana and their derivatives or legal substances used improperly, such as prescription drugs and inhalants like nail polish or gasoline.Drug addiction can be physical, psychological, or both. Physical dependence refers to the physiological effects of drug use. On the other hand, using a drug to numb unpleasant feelings, to relax, or to satisfy cravings are examples of psychological addiction. Physical addiction is characterized by ‘tolerance’ - the need for increasingly larger doses in order to achieve the initial effect and withdrawal symptoms when the user stops.
Signs and Symptoms of Drug Abuse: -
The more drug use begins to affect and control a person's life, the more likely it is that he or she has a drug problem. Drug abusers often try to conceal their symptoms and downplay their problem. However, there are a number of warning signs you can look for:
· Engaging in secretive or suspicious behaviors, such as making frequent trips to the restroom, basement, or other isolated areas where drug use would be undisturbed.
· Talking incoherently or making inappropriate remarks.
· Sudden changes in work or school attendance and quality of work or grades.
· Talking about drugs all the time and pressuring others to use.
· Angry outbursts, mood swings, irritability, manic behavior, or overall attitude change.
· Expressing feelings of exhaustion, depression, and hopelessness.
· Deterioration of physical appearance and grooming.
· Frequently borrowing money, selling possessions, or stealing items from employer, home, or school.
· No longer spending time with friends who do not use drugs and/or associating with known users.
The path to drug addiction begins with the act of taking drugs. Compulsive, drug craving, seeking, and use that persist even in the face of negative consequences characterize drug addiction. It is easier to prevent and stop drug addiction during the initial stages before a person becomes compulsively addicted to drugs.
About Author
DrugAlcoholTest.com is an online store offering Drug Test and drug screening products in several formats including blood, urine and oral drug test kits. These drug-testing kits can be used discreetly for at home drug test or for random employee Drug Testing . Some of the popular products are Marijuana Drug Test, Breathalyzer and Saliva Drug Test Products.
Source: ArticleTrader.com
Drug Treatment Psoriasis Specific links
Drug Treatment Psoriasis News
XenoPort Submits Investigational New Drug Application for XP23829 as a Potential Treatment of RRMS
XenoPort, Inc. announced today that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration to begin clinical studies of XP23829 as a potential treatment for relapsing-remitting multiple sclerosis .
Read more...Eisai Receives Positive CHMP Opinion for Zonegran® (Zonisamide) Monotherapy Treatment for Epilepsy
HATFIELD, England, May 28, 2012 /PRNewswire/ Eisai also receives CHMP recommendation for EU approval of Fycompa(R)(perampanel) Eisai announced today that the European Medicines Agency´s Committee for Medicinal Products for Human Use (CHMP) …
Read more...For Moderate to Severe Psoriasis, Surveyed U.S. Dermatologists Would Accept a Substantial Decrease in Efficacy ...
Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe psoriasis, surveyed U.S.
Read more...Press Release
XenoPort Inc. Posted on:24 May 12 XenoPort, Inc. (Nasdaq:XNPT) announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin clinical studies of XP23829 as a potential treatment for relapsing-remitting multiple sclerosis (RRMS). Following clearance of the IND by the FDA, the first Phase 1 clinical trial to be conducted ...
Read more...Idera Pharmaceuticals Announces Presentation of Preclinical Data of IMO-8400 in Both Lupus and Psoriasis Models
Idera Pharmaceuticals, Inc. today announced that it will be presenting data from preclinical studies of its Toll-like receptor inhibitor, IMO-8400, in models of systemic lupus erythematosus and psoriasis, which suggest that IMO-8400 may be useful for the treatment of both indications.
Read more...FDA staff question Pfizer arthritis drug benefits
WASHINGTON (Reuters) - U.S. drug reviewers on Monday questioned whether the benefits of Pfizer Inc's experimental treatment for rheumatoid arthritis outweighed its risks of cancerous cells and infections. The Food and Drug Administration staff said the drug, called tofacitinib, appeared to reduce swollen and tender joints during clinical trials. But the staff questioned the method of analyzing X ...
Read more...Research and Markets: Psoriasis - Oral and Novel Biologics to Change Future Market Dynamics
Research and Markets has announced the addition of the "Psoriasis - Oral and Novel Biologics to Change Future M
Read more...Data from Idera IMO-8400 preclinical studies for SLE and psoriasis presented at AAI meeting
Idera Pharmaceuticals, Inc. today announced data from preclinical studies of IMO-8400, demonstrating a novel mechanism of action that may be applicable to the treatment of systemic lupus erythematosus (SLE) and psoriasis. IMO-8400 is an inhibitor of specific Toll-like receptors (TLRs).
Read more...Eisai Gains Positive CHMP Opinion for Fycompa® (perampanel) First in a new Class of Treatment for Focal Epilepsy
HATFIELD, England, May 28, 2012 /PRNewswire/ CHMP also issues positive opinion for monotherapy use of Eisai´s Zonegran(R) (zonisamide) Eisai announced today that the European Medicines Agency´s Committee for Medicinal Products for Human Use …
Read more...Idera Pharmaceuticals Announces Efficacy Data for IMO-8400 in Preclinical Models of Lupus and Psoriasis
Idera Pharmaceuticals, Inc. today announced data from preclinical studies of IMO-8400, demonstrating a novel mechanism of action that may be applicable to the treatment of systemic lupus erythematosus and psoriasis.
Read more...